Abbott to pay $1.6B over misbranding

Abbott Laboratories said on Monday it agreed to pay $1.6 billion to resolve civil and criminal allegations related to the promotion of anti-seizure drug Depakote for unapproved uses.

WASHINGTON (AP) -- Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration....

Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.

By Mel Daris:Abbott Laboratories (ABT) is facing enormous costs for its decisions in marketing Depakote, its anti-seizure drug. The company marketed Depakote for uses it had not been approved for, and it downplayed the potential risks involved with taking the drug.

NEW ORLEANS (AP) — Now that a $4 billion plea deal has resolved BP's criminal liability for the massive Gulf of Mexico oil spill nearly three years ago, the company will turn its focus to a trial that could potentially cost it billions of dollars more in civil penalties.

A federal court in Virginia formally sentenced Abbott Laboratories for its off-label promotion of its antiseizure drug Depakote, ordering it to pay $700 million as part of a previously announced $1.6 billion settlement.

A federal court in Virginia formally sentenced Abbott Laboratories for its off-label promotion of its antiseizure drug Depakote, ordering it to pay $700 million as part of a previously announced $1.6 billion settlement.

(Reuters) - Ista Pharmaceuticals Inc pleaded guilty on Friday to charges it used kickbacks and improper marketing to boost sales of a drug meant to treat eye pain and agreed to pay $33.5 million to settle criminal and civil liability, the U.S.